aon glp 1 | Professional Services Study: GLP-1s Lower Healthcare Costs

Clinical trial results discussed in this article - STEP 1 (14.9% average body weight loss with semaglutide), SURMOUNT-1 (20.9% average body weight loss with tirzepatide), and SELECT (20% reduced risk of major cardiovascular events with FDA-approved Wegovy in a specific patient population) - relate to studied active ingredients and specific FDA-approved formulations in controlled trial populations and should not be interpreted as guaranteed outcomes for any individual patient or compounded formulation

Studies have re-emerged that demonstrating the efficacy of KD in patients with drug-resistant epilepsy and some pediatric epilepsy syndromes

4, 5, 6, 7 GIP is secreted from K cells in the proximal small bowel and binds to GIP receptors expressed by pancreatic islet cells, as well as to receptors in adipose tissue and the brain

For the majority of patients, injectable dulaglutide was selected due to the ease of use of the delivery device and the absence of a need for titration to reach the therapeutic dose

The limitation is the delivery gap: the data underpins applied-to-skin use far more than injected use